Drug
Peginterferon Alfa 2A
Peginterferon Alfa 2A: highest development phase Post-Market, developed by Chugai, Roche. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Chugai, Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Peginterferon alfa-2a NCT02570191 | Post-Market | Hepatitis B, Chronic |
| peginterferon alfa-2a NCT00144469 | Phase 3 | Chronic Hepatitis C |
Latest
No recent events.
Follow Peginterferon Alfa 2A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.